IVIG, Steroids or Plasma Exchange for CIDP: How the Three Treatments Differ

The neurologist slides a single sheet across the desk. Three columns, three words at the top: immunoglobulin, steroids, plasma exchange. ‘Any of these could be your starting point,’ she says, and then the sentence that sends most people home to search the internet late into the night: ‘There isn’t a wrong answer here.’ For someone whose feet have gone numb over the past four months and who now grips the banister with both hands, a menu of equally reasonable options feels less like reassurance and more like a test with no answer key.

That sheet is where the question of ivig vs plasma exchange for cidp, with steroids as the quiet third contender, really lives. Not in a laboratory, but in a consulting room where a person has to weigh a needle in the arm every few weeks against a daily tablet against a machine that filters their blood.

This article walks through what each option actually does, what the trials genuinely showed, and where the honest uncertainties sit, so that conversation can be a real one.

What is CIDP, and why does it need treating at all?

Chronic inflammatory demyelinating polyneuropathy, shortened to CIDP, is a condition in which the immune system attacks the insulating coating of the peripheral nerves. That coating is called myelin: think of it as the rubber sleeve around an electrical cable. Strip it away and the signal slows, stutters or fails to arrive. In CIDP the damage is ‘chronic’ because, by definition, symptoms progress for at least eight weeks, which is the main feature that separates it from its short-lived cousin Guillain-Barré syndrome (NINDS).

The result is usually weakness and altered sensation on both sides of the body, often starting in the feet and hands. People describe walking on cotton wool, dropping keys, or climbing stairs as if wearing lead boots. Because it is a polyneuropathy, meaning many nerves are involved at once, the pattern is typically symmetrical.

Why treat early? Myelin can regrow, and a nerve that has only lost its coating can recover remarkably well. The nerve fibre inside, the axon, is a different story. Prolonged inflammation begins to injure the axon itself, and axonal loss is far harder to reverse. The NINDS notes that untreated CIDP can lead to permanent nerve damage, which is exactly why neurologists tend to move quickly once the diagnosis is secure (NINDS).

Diagnosis rests on the clinical picture, nerve conduction studies that measure how fast signals travel, and sometimes a lumbar puncture showing raised protein in the spinal fluid. None of this is something to attempt at home from a symptom list. What matters for this article is a simpler idea: CIDP is an immune attack on nerve insulation, and every one of the three treatments works by calming or removing that attack.

How do IVIG, steroids and plasma exchange actually work?

Each treatment tackles the same immune misfire from a different angle, and understanding that angle explains almost everything about how they behave.

Intravenous immunoglobulin, or IVIG, is a concentrated preparation of antibodies pooled from thousands of blood donors, given by drip into a vein. Nobody fully understands why flooding the body with other people’s antibodies quiets an autoimmune attack, but several mechanisms are well described: the infused antibodies can neutralise harmful ones, block the receptors that immune cells use to attack tissue, and dampen inflammatory signalling (Cochrane IVIG review). A subcutaneous form, injected under the skin rather than into a vein, delivers the same product more slowly and is used mainly for maintenance.

Corticosteroids, often just called steroids, are synthetic versions of cortisol, a hormone the body already makes. At treatment strength they suppress the immune system broadly, reducing the production of inflammatory chemicals and the activity of the white cells doing the damage (Cochrane corticosteroids review). Prednisolone and prednisone are the oral forms most often discussed; intravenous pulses of methylprednisolone are another approach. They are not targeted; they turn down the whole immune orchestra rather than a single instrument.

Plasma exchange, also called plasmapheresis, is mechanical rather than chemical. Blood is drawn out through a needle or catheter, passed through a machine that separates the liquid plasma from the blood cells, and the cells are returned with a replacement fluid such as albumin (Cleveland Clinic). Since the harmful antibodies live in the plasma, removing the plasma removes them. Nothing is added to suppress the immune system, which is why the effect is quick but temporary: the body simply makes new antibodies.

Fast and washable, slow and broad, or borrowed and blocking. Hold those three images in mind for the comparisons that follow.

IVIG vs plasma exchange for CIDP: what the trials really show

Here is the honest headline: the two treatments have never been shown to differ meaningfully in how many people they help. The Cochrane review of plasma exchange for CIDP found only two randomised trials, together involving 59 participants, and concluded that plasma exchange produced significant short-term improvement in disability and nerve conduction compared with sham treatment (Cochrane plasma exchange review). Small numbers, but a clear signal.

IVIG has a larger evidence base. The Cochrane review identified five placebo-controlled trials with 269 participants and found that IVIG improved disability at two to six weeks more often than placebo (Cochrane IVIG review). The largest of those trials, known as ICE, reported that around 54% of people receiving IVIG had a meaningful improvement in disability compared with about 21% on placebo (Hughes 2008, summarised in the Cochrane review).

When the two were compared head to head in a small crossover trial included in both Cochrane reviews, the improvements were similar. Neither treatment emerged as clearly superior, and the review authors were explicit that the evidence was too limited to declare a winner (Cochrane plasma exchange review).

Where they diverge is in what happens after the course ends. The plasma exchange review noted that improvement tended to fade within weeks in a substantial share of participants, which is exactly what the mechanism predicts: the antibody factory keeps running (Cochrane plasma exchange review). IVIG’s effect also wanes, which is why most people who respond need repeated infusions, but the interval is usually longer and the logistics simpler.

So when someone asks which is better, plasmapheresis or IVIG, the evidence-based answer is uncomfortable but real: for the short-term aim of getting nerves working again, they appear comparable. The choice turns on practicality, access to specialist equipment, vein quality, and how a particular person’s body tolerates each.

Steroids or IVIG for CIDP: where corticosteroids fit

Steroids are the oldest of the three and, in some ways, the most underrated. They are taken as tablets, they are inexpensive to health systems, and they can produce something the other two rarely do on their own: long, treatment-free remissions in a subset of people.

The evidence, however, is thinner than many assume. The Cochrane corticosteroids review found only one small randomised trial of oral prednisone versus no treatment, with 35 participants, showing a modest benefit in disability over twelve weeks that did not reach conventional statistical significance (Cochrane corticosteroids review). The reviewers judged the evidence low quality. That does not mean steroids do not work; clinical experience over decades and the treatment’s use in every major guideline say otherwise. It means the formal trial base is small.

Two trials compared steroids directly with IVIG. One, comparing oral prednisolone with IVIG, found no significant difference in disability improvement at two weeks (Cochrane corticosteroids review). The other compared pulsed intravenous methylprednisolone with IVIG over six months. More people stopped the steroid early because it was not working or because of side effects, but among those who did respond to steroids, remissions after stopping tended to last longer (Cochrane corticosteroids review).

That trade-off is the heart of the steroids or IVIG question. Steroids take longer to show benefit, weeks rather than days, and a person may deteriorate before improving. They also carry a long list of cumulative harms, covered later. In exchange, some people gain a durable remission that IVIG’s borrowed antibodies cannot provide.

Neurologists therefore often reach for steroids when a person has predominantly sensory or slowly progressive disease, when infusion access is difficult, or when a disease-modifying rather than maintenance strategy is the goal. They tend to avoid them in people with diabetes, osteoporosis or a history of psychiatric illness, where the harms weigh heavier. As always, that judgement sits with the treating team.

Who is usually offered which treatment first, and who is asked to wait?

Guidelines from neurology bodies place all three on the first line, and the choice is deliberately individualised. Still, some patterns are consistent enough to describe.

IVIG is often the opening move for people with significant motor weakness, especially when walking or hand function is deteriorating quickly. Its speed, usually within two to six weeks in the trials, and its relatively predictable side-effect profile make it a common default (Cochrane IVIG review). It is also generally preferred for children, in pregnancy, and for people with conditions such as diabetes where steroids would be risky.

Corticosteroids are more likely to be suggested when disease is slower, when sensory symptoms dominate, when the person has good general health without steroid-sensitive conditions, or when there is a strong wish to avoid regular infusions. Some neurologists prefer them for the chance at a durable remission.

Plasma exchange tends to be reserved for situations where the other two have failed, where IVIG is unavailable or poorly tolerated, or where a very rapid response is needed and the person has good venous access. Because it requires apheresis equipment and trained staff, it is less often a first choice in routine outpatient care (Cleveland Clinic).

Who is asked to wait? People whose diagnosis is not yet secure. CIDP has several mimics, including hereditary neuropathies and neuropathies linked to abnormal proteins in the blood, and treating the wrong condition exposes someone to risk without benefit. Neurologists may also observe someone with very mild, stable symptoms, since treatment is not without harm and some cases plateau on their own (NINDS). And a small group with a variant of CIDP driven by antibodies against nerve-junction proteins responds poorly to IVIG altogether; identifying them early changes the whole plan.

None of this is a queue to be argued with. It is a triage of benefit against risk for one person at a time.

IVIG, steroids and plasma exchange side by side

Numbers help here, so long as they are read as typical ranges from the cited trials rather than promises. The table below draws on the three Cochrane reviews and the Cleveland Clinic overview of plasmapheresis.

Feature	IVIG	Corticosteroids	Plasma exchange
How it works	Pooled donor antibodies block and neutralise the immune attack	Broad suppression of immune activity	Mechanical removal of antibody-containing plasma
Route	Intravenous drip (subcutaneous form for maintenance)	Oral tablets or intravenous pulses	Blood drawn, filtered and returned via needle or catheter
Typical time to benefit in trials	Two to six weeks (Cochrane IVIG review)	Weeks to months; slower than the other two (Cochrane corticosteroids review)	Days to two weeks (Cochrane plasma exchange review)
How long benefit lasts	Wanes over weeks; repeat courses usually needed	Can produce lasting remission in some responders	Often fades within weeks once course ends
Common side effects	Headache, chills, fatigue, nausea, skin reactions	Weight gain, mood change, raised blood sugar, sleep disturbance	Low blood pressure, tingling from low calcium, bruising at access site
Serious but uncommon risks	Blood clots, kidney injury, aseptic meningitis	Osteoporosis, cataracts, infection, diabetes with long use	Bleeding, infection at catheter, allergic reaction to replacement fluid
Setting	Infusion unit or home service	Home	Specialist apheresis unit

Two observations stand out. First, the row that separates the treatments is not effectiveness; it is durability and burden. Second, every option has a serious-risk row, which is why ‘safe’ is never the right word for any of them. ‘Well characterised’ is closer to the truth.

What actually happens during an IVIG infusion?

Most people picture something dramatic. The reality is closer to a long, dull afternoon with a cannula in one arm.

A first course is usually given over several consecutive days in an infusion unit or day ward, because the total amount of immunoglobulin is spread out to reduce side effects. Each session can last several hours. A nurse places a small cannula, checks blood pressure, pulse and temperature, and starts the drip slowly, increasing the rate if all is well. The neurologist sets the plan; the nurse watches the person.

Many units give simple premedication, such as paracetamol or an antihistamine, to blunt the most common reactions: headache, chills, flushing and a flu-like heaviness. Drinking well before and after the infusion is routinely advised, since good hydration reduces the risk of the rarer kidney and clotting complications. People are often encouraged to bring a book, a charger and warm socks.

After the initial course, the pattern changes. If the person responds, maintenance infusions are repeated at intervals the neurologist judges from the pattern of benefit and wear-off, typically measured in weeks. Some services deliver these at home with a visiting nurse. Some people switch to the subcutaneous form, which they or a family member can give at home after training; the PATH trial showed that continuing subcutaneous immunoglobulin after IVIG reduced relapses compared with placebo over 24 weeks, with relapse in roughly a third versus about two thirds (van Schaik 2018, indexed on PubMed).

What does improvement feel like? Rarely a switch flipping. More often a week later someone notices they climbed the stairs without pulling on the rail, or the tingling has retreated from the shins back to the toes. Neurologists track this with standardised scales of grip strength and walking, because memory is an unreliable witness and the decision to continue rests on measurable change.

How risky is plasmapheresis, and what happens during a plasma exchange?

Plasma exchange sounds like the most invasive of the three, and in one sense it is: it needs a machine, a specialist team and reliable access to the bloodstream. Yet in experienced hands its complication rate is low, and most problems are minor and immediately fixable.

The session begins with vascular access. Some people have veins robust enough for two large needles, one to draw blood and one to return it. Many need a temporary catheter placed in a large vein in the neck or groin, which stays in for the course. Blood flows continuously into the apheresis machine, which spins or filters it to separate plasma from cells. The plasma is discarded; the cells are mixed with a replacement fluid, usually a protein solution called albumin, and returned (Cleveland Clinic). A single exchange typically takes a couple of hours, and a course consists of several exchanges over roughly one to two weeks, though the exact number is set by the treating team (Cochrane plasma exchange review).

The commonest sensations are odd rather than dangerous. The anticoagulant used to stop blood clotting in the tubing, citrate, temporarily lowers calcium levels and causes tingling around the mouth and fingertips; a calcium supplement through the line settles it. Blood pressure can dip as fluid shifts, producing light-headedness that responds to slowing the machine. Bruising and soreness at the access site are routine (Cleveland Clinic).

The serious risks are rarer: bleeding, because clotting proteins are removed along with the antibodies; infection at a catheter site; allergic reaction to the replacement fluid; and, very uncommonly, a clot or air entering the line. Units monitor clotting and blood counts throughout to catch these early.

So, how risky is plasmapheresis? Roughly as risky as any procedure involving a central catheter and large fluid shifts: real, monitored, and usually manageable. The bigger practical issue is not danger but logistics and the short-lived benefit.

What the following weeks usually look like after starting treatment

Timelines matter in CIDP because the three treatments run on different clocks, and knowing the clock prevents unnecessary panic.

After IVIG, the trials measured improvement at two to six weeks (Cochrane IVIG review). In practice some people feel steadier within days, while others notice nothing until the second or third week. A neurologist will usually reassess formally around that point with the same strength and walking measures used before treatment. If there is clear benefit, the conversation turns to maintenance intervals. If there is none after an adequate trial, the team may repeat a course or move to another option rather than persisting indefinitely.

Plasma exchange runs faster. Benefit often appears during or shortly after the course, within days to two weeks, but the reviews consistently noted that gains faded over the following weeks in many participants (Cochrane plasma exchange review). For this reason plasma exchange is rarely a stand-alone plan; it is more often a bridge to IVIG or steroids, or a rescue during a severe relapse.

Steroids run slowest. Improvement is typically measured over weeks to months, and it is common to feel no different, or even slightly worse, in the first few weeks (Cochrane corticosteroids review). Meanwhile the side effects arrive on schedule: appetite, disturbed sleep and mood shifts often show up before any nerve benefit does. Neurologists usually arrange blood sugar checks, bone protection and blood pressure monitoring alongside.

Across all three, physiotherapy runs in parallel. Muscles weakened by months of poor nerve signalling do not spring back simply because the signals return; they need retraining. Occupational therapy addresses hand function and home safety. Fatigue, often the most persistent symptom, improves more slowly than strength and sometimes lags by months.

The practical takeaway is to agree, before starting, what ‘working’ will look like and when it will be judged. That single conversation removes most of the anxiety of the waiting weeks.

What happens if IVIG doesn't work for CIDP?

This is the question people whisper at the end of the appointment, and it deserves a plain answer: a meaningful minority of people do not respond to IVIG, and there is a well-trodden path for them.

First, the team checks the diagnosis. In the ICE trial about 54% responded to IVIG (Hughes 2008, via the Cochrane IVIG review), which means roughly half did not, and a share of those non-responders in real-world clinics turn out to have something other than typical CIDP. Repeat nerve studies, blood tests for abnormal proteins, and testing for antibodies against nerve-junction proteins such as neurofascin and contactin are common steps. People with those antibodies rarely improve with IVIG and often do better with treatments that target antibody-producing B cells, a strategy still supported mainly by observational evidence rather than large randomised trials.

Second, the team asks whether the trial was adequate. Some people need a second course before benefit shows; others respond but wear off so quickly that the interval was simply too long.

Third comes the switch. Corticosteroids and plasma exchange remain first-line alternatives and either may be tried next, sometimes in combination with IVIG for a period. Beyond the first line, neurologists may consider immunosuppressant medicines borrowed from transplant and rheumatology practice. The evidence for these in CIDP is weak; Cochrane reviews of immunosuppressants have generally found trials too small to show benefit, which is why they are described as options rather than proven therapies. Newer targeted agents that block a receptor involved in recycling antibodies have been studied in CIDP, but they are recent and their long-term place is still being defined.

What people should not conclude is that a poor response to IVIG means nothing else will help. It means the map needs redrawing, and redrawing it is the neurologist’s job.

Side effects of IVIG, steroids and plasma exchange, compared honestly

Efficacy questions get the attention; side-effect questions determine whether someone actually stays on a treatment. The three profiles are strikingly different in character.

IVIG side effects cluster around the infusion itself. Headache is the most frequent, sometimes severe enough to mimic migraine. Chills, low-grade fever, nausea, muscle aches and fatigue in the day or two afterwards are common and usually settle. Rashes, sometimes appearing a week later on the hands, are well described. The rare serious events are the ones neurologists screen for: blood clots in the legs or lungs, kidney strain, a sterile inflammation of the brain lining called aseptic meningitis, and breakdown of red blood cells. Slow infusion rates and good hydration reduce these risks, and people with prior clots or kidney disease are assessed carefully (Cochrane IVIG review).

Steroid side effects are cumulative and systemic. Early on: increased appetite, weight gain, fluid retention, mood swings, insomnia and a rise in blood sugar that can unmask diabetes. Over months: thinning bones, cataracts, skin fragility, muscle weakness in the hips and shoulders (which can be confused with CIDP itself), raised blood pressure and heightened infection risk (Cochrane corticosteroids review). In the head-to-head trial with IVIG, more participants withdrew from the steroid arm because of side effects or lack of effect. Bone protection and blood sugar monitoring are standard companions.

Plasma exchange side effects are procedural and mostly immediate: the citrate tingling, blood pressure dips, and access-site bruising described earlier, plus the catheter-related risks of infection and bleeding (Cleveland Clinic). Once the course ends, so do the side effects; there is no lingering chemical footprint.

The pattern is worth stating outright. IVIG’s harms arrive around infusion days and mostly leave. Steroids’ harms accumulate quietly. Plasma exchange’s harms belong to the procedure room. Which profile a person can live with is a genuinely individual judgement, and a legitimate reason to prefer one first-line treatment over another.

Is there a 'most effective treatment for CIDP'?

The search results promise a ranking. The evidence refuses to supply one, and understanding why is more useful than any league table.

Randomised trials in CIDP are small. The largest placebo-controlled IVIG study enrolled 117 people; the entire plasma exchange evidence base is 59 participants; the only steroid-versus-nothing trial had 35 (Cochrane IVIG, plasma exchange and corticosteroids reviews). In studies of that size, a real difference of, say, ten percentage points in response rate would be invisible. The head-to-head comparisons that exist found no significant differences, but ‘no difference found’ in a small trial is not the same as ‘proven equal’.

Effectiveness also depends on what is being measured. Short-term disability improvement at a few weeks favours nobody in particular. Speed favours plasma exchange and IVIG. Durability after stopping favours steroids in those who respond. Freedom from infusion visits favours steroids or subcutaneous immunoglobulin. Freedom from long-term metabolic harm favours IVIG and plasma exchange. Choose the outcome, and the ‘most effective’ treatment changes.

Then there is the individual. Roughly half to two thirds of people respond to whichever first-line treatment is tried, and a person who fails one often responds to another (NINDS). That fact alone tells you the three are not interchangeable at the level of the individual, even if they look similar in group averages. Some nervous systems simply answer to one signal and not the others, for reasons that are only beginning to be understood through antibody testing.

The defensible statement, and the one guidelines make, is this: IVIG, corticosteroids and plasma exchange are all effective first-line options with comparable short-term benefit, and the choice should reflect disease severity, other health conditions, practicalities and the person’s own priorities. Anyone promising a single best treatment for everyone is reading a chart that does not exist.

What people often get wrong about IVIG vs plasma exchange for CIDP

Some myths are harmless. In CIDP, a few of them lead people to refuse good treatment or cling to failing ones, so they are worth naming.

‘Plasma exchange is the last resort, so it must be the strongest.’ It is often used later, but for reasons of logistics and durability, not potency. In the trials its short-term effect was comparable to IVIG (Cochrane plasma exchange review). Being reserved is not the same as being superior.

‘IVIG is a cure that fixes the immune system.’ It does not reset anything. It borrows antibodies that suppress the attack while they circulate, and the effect fades as they are cleared, typically over weeks. That is why most responders need ongoing treatment (Cochrane IVIG review).

‘Steroids are old-fashioned and neurologists only use them when they cannot get IVIG.’ Steroids remain a guideline first-line treatment and are the only one of the three with a realistic prospect of a lasting treatment-free remission in some people (Cochrane corticosteroids review).

‘If the first treatment doesn’t work, nothing will.’ People who fail one first-line option frequently respond to another; non-response is a reason to reassess and switch, not to give up (NINDS).

‘Feeling worse in the first fortnight means the treatment is harming me.’ With steroids in particular, side effects arrive before benefit, and CIDP itself may still be progressing during the lag. The team should be told, but it is often the expected shape of the curve.

‘Plasma exchange removes toxins and cleanses the blood.’ It removes plasma proteins, including the antibodies causing the trouble, along with useful proteins that the body then replaces. It has nothing to do with detoxification in the wellness sense.

‘IVIG from more donors is stronger.’ All licensed products are pooled from thousands of donors and standardised; there is no evidence that any particular preparation outperforms another for CIDP.

Every one of these misunderstandings shares a root: treating the three options as rungs on a ladder rather than as different tools for different hands.

Questions to ask your care team

The most useful appointments are the ones where the person has thought about what they want to know. These questions are drawn from what CIDP patients most often say they wish they had asked.

• How confident are you in the diagnosis, and have the main mimics been excluded? Would antibody testing change the plan?
• Why are you suggesting this particular first treatment for me rather than the other two?
• What will we measure to decide whether it is working, and when will we make that judgement?
• If it works, what does maintenance look like: how often, where, and for how long before we try reducing?
• If it does not work, what is the next step, and how long would we wait before switching?
• Which side effects should I expect on infusion or procedure days, and which ones should make me call you?
• Do any of my other conditions or medicines make one option riskier for me?
• Is home infusion or subcutaneous immunoglobulin something I could move to later?
• Should I be referred for physiotherapy or occupational therapy alongside treatment?
• Are there any clinical trials I might be eligible for?

A few practical additions help too. Ask who to contact between appointments and how quickly they respond. Ask whether the unit has a written information sheet on the chosen treatment. And ask, plainly, what the team would consider a good outcome for someone in your situation, because a realistic shared target beats a hopeful vague one.

It is entirely reasonable to bring someone along, to record the conversation with permission, or to ask for a second appointment before deciding. Starting a long-term immune treatment is not an emergency in most cases, and a day or two to absorb the information rarely changes the outcome. The decision belongs to the person and their treating team together.

When to call your doctor

CIDP treatment is a long relationship with a neurology service, and knowing what warrants a same-day call, rather than a note for the next appointment, is part of managing it well.

Call urgently, or seek emergency care, if any of the following develop: new difficulty breathing, swallowing or speaking, since weakness spreading to those muscles is rare in CIDP but serious; sudden severe headache with a stiff neck, fever or light sensitivity after an IVIG infusion, which can signal aseptic meningitis; chest pain, breathlessness, or a swollen, painful calf in the days after IVIG, which may indicate a blood clot; passing very little urine or noticing dark urine after infusion, a possible sign of kidney or red cell problems; fever, redness or pus at a plasma exchange catheter site; or any bleeding that will not stop.

Contact the team the same day if weakness worsens rapidly over hours or a few days rather than weeks, if a fall occurs, if a new rash spreads widely, or if blood sugar readings climb sharply on steroids. People taking steroids should also report severe mood change, persistent vomiting, or signs of infection, because steroids can mask the usual warning signals.

Do not stop, skip or alter any treatment because of side effects without speaking to the prescriber. Abrupt steroid withdrawal in particular can be dangerous, and delayed infusions can allow relapse. The team can nearly always adjust the plan; they cannot adjust what they do not know about.

Between the red flags, a simple habit helps: keep a short weekly note of what you could and could not do, from opening jars to climbing stairs, and bring it to every review. It turns the vague question ‘how have you been?’ into evidence, and evidence is what this whole condition turns on.

Frequently asked questions

Which is better, plasmapheresis or IVIG for CIDP?

Neither has been shown to be better in randomised trials. The Cochrane reviews found comparable short-term improvement in disability with both, and a small direct comparison found no significant difference. IVIG is usually chosen first because it is easier to deliver and its benefit lasts somewhat longer, while plasma exchange needs specialist equipment and often wears off within weeks. The right choice depends on severity, vein access, other conditions and personal preference.

What is the most effective treatment for CIDP?

No single treatment has been proven most effective. IVIG, corticosteroids and plasma exchange are all first-line options with similar short-term benefit in the available trials, which were small. They differ in speed, durability and side effects rather than in headline effectiveness. Because people who fail one option often respond to another, neurologists individualise the choice rather than following a fixed ranking.

How risky is plasmapheresis?

In experienced units the risks are real but usually manageable. Common effects include tingling from temporarily low calcium, dips in blood pressure and bruising at the access site. Less common but more serious risks include bleeding, infection at a catheter site and allergic reactions to the replacement fluid. Staff monitor blood counts, clotting and vital signs throughout each session to catch problems early.

What happens if IVIG doesn't work for CIDP?

The team first rechecks the diagnosis, since several conditions mimic CIDP and some antibody-associated variants respond poorly to IVIG. They also consider whether the trial was long enough. If IVIG has genuinely failed, corticosteroids or plasma exchange are the usual next steps, sometimes combined. Beyond those, immunosuppressant medicines or newer targeted agents may be considered, though the trial evidence for them is weaker.

Steroids or IVIG for CIDP: which do neurologists prefer?

It depends on the person. IVIG is often preferred for rapidly worsening weakness, for children, in pregnancy, and for people with diabetes or bone thinning where steroids carry extra risk. Steroids may be favoured for slower or sensory-predominant disease, for people who want to avoid infusions, or when a durable remission is the goal. Trials comparing the two found similar short-term benefit but more withdrawals for side effects on steroids.

How long does IVIG take to work in CIDP?

In the randomised trials, improvement in disability was measured at two to six weeks after treatment. Some people notice change within days; others need most of that window or a second course. Neurologists usually reassess with standardised strength and walking measures around that point, and if there is no benefit after an adequate trial they consider switching rather than continuing indefinitely.

Does plasma exchange remove good antibodies too?

Yes. Plasma exchange removes the whole liquid portion of the blood, including protective antibodies, clotting proteins and other useful plasma components along with the harmful ones. The body replaces them over the following days, which is one reason bleeding risk and infection risk are monitored during a course. The replacement fluid, usually albumin, restores volume but not antibodies.

Can CIDP treatment be stopped once symptoms improve?

Sometimes, under neurology supervision. A proportion of people, particularly steroid responders, achieve remissions that persist after treatment ends. Others relapse when treatment is withdrawn or spaced out, which is why neurologists often test this gradually by extending intervals while monitoring strength. Stopping any CIDP treatment abruptly without medical advice is not recommended, and abrupt steroid withdrawal can be dangerous.

Is subcutaneous immunoglobulin as good as IVIG for CIDP?

For maintenance, the evidence is encouraging. The PATH trial found that people who had responded to IVIG and then continued with subcutaneous immunoglobulin relapsed less often than those switched to placebo over 24 weeks. It is given at home under the skin after training, avoiding infusion visits. It is not generally used as the initial treatment to bring CIDP under control.

Do IVIG side effects get worse with repeated infusions?

Usually not. Most reactions, such as headache, chills and fatigue, occur around each infusion and tend to become predictable and manageable with slower rates, hydration and simple premedication. Serious complications such as blood clots or kidney strain remain uncommon and are screened for before each course. Any new or escalating reaction should be reported to the infusion team so the plan can be adjusted.

References

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), National Institute of Neurological Disorders and Stroke (NIH)
• Chronic inflammatory polyneuropathy, MedlinePlus Medical Encyclopedia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.